ArticleMikrochimica acta2026
Advancing drug discovery: a colorimetric dual-platform system based on Fe-MoO
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Developing efficient, low-cost, and portable screening methods for α-glucosidase inhibitors (AGIs) is of great significance for discovering natural antidiabetic drugs. Accordingly, this study constructed a colorimetric dual-platform system utilizing Fe-doped MoOx (Fe-MoOv) nanozymes with superior peroxidase-like activity, featuring both high-throughput capability and portability. This system functions by linking α-glucosidase (α-Glu) activity to a colorimetric readout: active α-Glu leads to a colorless output, whereas its inhibition by an AGI preserves an intense blue color, allowing for straightforward visual identification. This mode gave rise to two platforms: the high-throughput screening (HTS) platform facilitated parallel analysis of 96–384 samples using a microplate reader for large-scale library screening, while the portable screening (PTS) platform provided rapid on-site assessment by delivering readable results within 46 min via a smartphone. Experimentally, the system was validated using acarbose as a model AGI, achieving detection limits as low as 0.00411 µM for the HTS platform and 0.092 µM for the PTS one, along with robust interference tolerance. Furthermore, the sensing system was successfully applied to screen seven pentacyclic triterpenoids as potential AGIs. All compounds were confirmed as active inhibitors with IC50 values clustering in the range 30–110 µM. Ursolic acid, the most potent inhibitor (IC50 = 30.23 µM), exhibited 3.5-fold greater potency than the least active one. Molecular docking further elucidated their interaction mechanisms with α-Glu. In summary, this study presents an innovative screening strategy that is efficient, low-cost, and user-friendly, offering a new approach for the development of natural antidiabetic drugs.
Indexed as
Identifiers
42018010What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.